Granocyte

Granocyte is an injectable solution containing the recombinant granulocyte colony‑stimulating factor lenograstim. It is supplied in a standard concentration for intravenous or subcutaneous administration and is marketed in the European Union as a prescription‑only hematopoietic growth factor. The product is used to support neutrophil recovery in patients undergoing chemotherapy, bone‑marrow transplantation, or stem‑cell mobilization, and it is classified under ATC code L03AA02 as part of standard supportive care protocols.

Granocyte is indicated for several hematologic conditions where neutrophil counts are compromised.

- Management of chemotherapy‑induced neutropenia to reduce infection risk. - Treatment of neutropenia following allogeneic or autologous bone‑marrow transplantation. - Mobilization of peripheral blood stem cells for collection prior to transplantation. - Support of neutrophil recovery in patients receiving high‑dose radiation therapy.

Adverse reactions to lenograstim are generally mild to moderate, but serious events can occur.

Common: - Bone pain, especially in the lower back or hips. - Mild fever or flu‑like symptoms. - Injection site erythema or discomfort. - Nausea or mild gastrointestinal upset.

Serious: - Splenic rupture or enlargement. - Acute respiratory distress syndrome (ARDS). - Severe allergic reactions such as anaphylaxis. - Capillary leak syndrome.

When prescribing Granocyte, clinicians should evaluate patient history and monitor for specific safety concerns.

- Assess baseline neutrophil counts and overall bone‑marrow function before initiation. - Use caution in patients with a history of splenic disorders or abdominal trauma. - Avoid in individuals with known hypersensitivity to lenograstim or any excipients. - Monitor for signs of infection, fever, or unexpected inflammation during therapy. - Consider dose adjustment or discontinuation if severe bone pain or systemic reactions develop. - Pregnancy and lactation status should be reviewed, as safety data are limited.

Lenograstim may interact with other medications or clinical conditions that affect immune function or hematopoiesis.

Avoid: - Concurrent use of other granulocyte colony‑stimulating factors or high‑dose corticosteroids without specialist guidance. - Live vaccines administered during treatment, due to altered immune response.

Use with caution: - Chemotherapeutic agents that cause profound myelosuppression, requiring close monitoring of blood counts. - Anticoagulants, as changes in platelet function may occur. - Immunosuppressive biologics, which could modify the efficacy of neutrophil recovery.